Replies to post #221133 on Biotech Values

[bladerunner1717]

Why the big drop in TRIL--11% as I type--on huge volume?


Bladerunner

[biocqr]

TRIL > ASH poster

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPaFc) Induces Responses in Both Injected and Non-injected Lesions
in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial

https://s22.q4cdn.com/183592819/files/ASH-2018-Poster-FINAL.pdf

CONCLUSIONS
• Single and multiple IL injections of up to 10 mg TTI-621
were well tolerated.

• 91% (20/22) of heavily pretreated MF/SS patients had a
reduction in CAILS scores in treated lesions; 41% (9/22) had
≥50% CAILS score decrease.

• Responses were rapid and occurred across all disease stages
following single and multiple TTI-621 injections of varying
doses.

• Similar CAILS-based changes were seen in adjacent noninjected
lesions, suggesting local regional effects that were
not confined to the site of injection.

• Continuation monotherapy led to further reductions in
CAILS scores in 3/4 evaluable patients and evidence of
systemic effects in one patient, suggesting treatment
beyond the two-week induction and rolling injections may
provide additional clinical benefit.

• Initial experience suggests a possible benefit to combining
TTI-621 with PEG-IFN-a2a.

• Emerging translational data demonstrate that IL TTI-621
administration leads to a rapid influx of macrophages and
CD8+ T cells.